H.C. Wainwright Reiterates Buy Rating, $1.25 Price Target on Akebia Therapeutics (AKBA)
Tweet Send to a Friend
H.C. Wainwright analyst Ed Arce reiterated a Buy rating and $1.25 price target on Akebia Therapeutics (NASDAQ: AKBA). The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
